Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).
OBJECTIVE
A Phase I/IIb multicenter study was conducted to evaluate the safety and immunogenicity of the anti-idiotypic antibody vaccine ACA125 that functionally imitates the tumor antigen CA125 in 119 patients with advanced ovarian carcinoma. A preliminary report on the initial 42 patients demonstrated safety and immunogenicity.


METHODS
Using the complete intention-to-treat population (n = 119) who received a mean of 9.7 ACA125 applications, survival was analyzed with respect to immunological responses.


RESULTS
In 81 patients (68.1%), a specific anti-anti-idiotypic antibody (Ab3) response could be induced. Additionally, the development of CA125-specific antibodies (Ab1') and antibody-dependent cell-mediated cytotoxicity of CA125-positive tumor cells was observed in 50.4% and 26.9% of patients, respectively. The median survival of all patients was 19.4 months (range, 0.5-56.1 months). Ab3-positive patients showed a significantly longer survival (median, 23.4 months; P < 0.0001) as compared with Ab3-negative patients (median, 4.9 months). A positive Ab3 response remained associated with longer survival when controlling for other prognostic factors including FIGO (International Federation of Gynecologists and Obstetricians) stage, response to and type of first-line chemotherapy, number of previous treatments, or concomitant antitumor therapy. With regard to safety, repeated vaccination was well tolerated. No serious adverse events related to the application of ACA125 occurred.


CONCLUSIONS
Although the uncontrolled design of this study prevents definitive conclusions with respect to subgroups, the data support a relationship between Ab3 response and survival time. Thus, the need for further randomized, controlled clinical trials to establish efficacy of the vaccine ACA125 seems to be indicated.
Reinartz
Silke
S
Center of Obstetrics and Gynecology, University of Marburg, Marburg, Germany. reinartz@med.uni-marburg.de
Köhler
Siegmund
S
Schlebusch
Harald
H
Krista
Karl
K
Giffels
Patrick
P
Renke
Kirsten
K
Huober
Jens
J
Möbus
Volker
V
Kreienberg
Rolf
R
DuBois
Andreas
A
Sabbatini
Paul
P
Wagner
Uwe
U
D000818:Animals; D018394:CA-125 Antigen / Q000276:immunology*; D019496:Cancer Vaccines / Q000627:therapeutic use / Q000633:toxicity*; D005260:Female; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D051379:Mice; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis
D018394:CA-125 Antigen; D019496:Cancer Vaccines; D007518:Isoantibodies